Citations

Showing 10 of 108083 citations.

Metastatic Canine Medullary Thyroid Carcinoma: A Case Report
Long, G. G., Clemmons, Roger M., Heath, Hunter

Mayo Clinic

Veterinary Pathology | August 3, 2017 | Volume: 17 | Issue: 3 | Pages: 323-330

10.1177/030098588001700306 | PMID 6966103 Get It

A medullary carcinoma of the thyroid in a dog first became evident because of a distant metastasis. The histologic characteristics of the tumor differ from those previously reported in dogs in that this tumor was highly malignant; anaplasia and mitotic figures were common. The diagnosis was substantiated by radioimmunoassay for calcitonin. Serotonin and 5-hydroxytryptophan also were elevated in the neoplastic tissue. The relation of the biochemical alterations to the clinical course was not clear.
Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation
Banerjee, Dipti, Roeker, Lindsey E. , Grogan, Martha , Poterucha, John J., Zeldenrust, Steve R., Edwards, Brooks S., Daly, Richard C. , Klarich, Kyle W. , Poterucha, John, Zeldenrust, Steve, Edwards, Brooks, Daly, Richard , Swiecicki, Paul Loren , Heimbach, Julie K. , Zeldenrust, Steven R., Gertz, Morie A. , Dispenzieri, Angela , Roeker, Lindsey

Mayo Clinic

Progress in Transplantation | August 3, 2017 | Volume: 27 | Issue: 3 | Pages: 246-250

10.1177/1526924817715463 | PMID 29187090 Get It

Background: Familial transthyretin amyloidosis is a disease caused by misfolded transthyretin aggregates that can impair multiple organ systems. Liver transplantation is the first-line treatment for familial transthyretin amyloidosis. Research Question: Our objective is to study outcomes and survival among patients with familial transthyretin amyloidosis after transplantation. Design: All patients undergoing orthotopic liver transplant for familial transthyretin amyloidosis at Mayo Clinic between 1997 and 2012 were reviewed. Baseline clinical characteristics, organs transplanted, and posttransplant clinical course were assessed. Results: Of the 40 patients, 7 patients had the V30M mutation and 33 had other mutations. Nineteen patients received liver only, 19 liver and heart, and 2 combined liver, heart, and kidney transplants. The 5-year overall survival was 85% for those receiving multiple organ transplant and 52% for those receiving liver transplant only ( P = .057). There was no difference in overall survival based on mutation (V30M vs other mutations), but survival was confounded by varied disease involvement and organs transplanted. Those who had early death (≤24 months from liver transplant) had a higher incidence of baseline peripheral neuropathy, autonomic neuropathy, lower modified BMI, and higher alkaline phosphatase. Discussion: Outcomes of orthotopic liver transplant in familial transthyretin amyloidosis are variable due to heterogeneity in mutations and patient status at the time of transplant. Familial transthyretin amyloidosis can progress, despite liver transplantation. Patients receiving combined liver, heart/kidney transplant demonstrated improved survival compared to liver transplant alone.
Factors Associated With Time to Site Activation, Randomization, and Enrollment Performance in a Stroke Prevention Trial
Brown, Robert D. , Roubin, Gary S., Howard, Virginia J. , Cesko, Eldina, Barrett, Kevin M. , Longbottom, Mary, Voeks, Jenifer H. , Brott, Thomas G. , Lal, Brajesh K. , Howard, George , Longbottom, Mary E, Demaerschalk, Bart M. , Chaturvedi, Seemant , Meschia, James F. , Howard, Virginia J , Howard, George

Mayo Clinic

Stroke | August 3, 2017 | Volume: 48 | Issue: 9 | Pages: 2511-2518

10.1161/strokeaha.117.016976 | PMID 28768800 Get It

Background and Purpose— Multicenter clinical trials attempt to select sites that can move rapidly to randomization and enroll sufficient numbers of patients. However, there are few assessments of the success of site selection. Methods— In the CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trials), we assess factors associated with the time between site selection and authorization to randomize, the time between authorization to randomize and the first randomization, and the average number of randomizations per site per month. Potential factors included characteristics of the site, specialty of the principal investigator, and site type. Results— For 147 sites, the median time between site selection to authorization to randomize was 9.9 months (interquartile range, 7.7, 12.4), and factors associated with early site activation were not identified. The median time between authorization to randomize and a randomization was 4.6 months (interquartile range, 2.6, 10.5). Sites with authorization to randomize in only the carotid endarterectomy study were slower to randomize, and other factors examined were not significantly associated with time-to-randomization. The recruitment rate was 0.26 (95% confidence interval, 0.23–0.28) patients per site per month. By univariate analysis, factors associated with faster recruitment were authorization to randomize in both trials, principal investigator specialties of interventional radiology and cardiology, pre-trial reported performance >50 carotid angioplasty and stenting procedures per year, status in the top half of recruitment in the CREST trial, and classification as a private health facility. Participation in StrokeNet was associated with slower recruitment as compared with the non-StrokeNet sites. Conclusions— Overall, selection of sites with high enrollment rates will likely require customization to align the sites selected to the factor under study in the trial. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT02089217.
Previously Unreported in Women Galactosidase Alpha Pro409Ser Variant Is Associated With Fabry Disease
Luis, Sushil Allen , Maleszewski, Joseph J. , Young, Phillip M. , Schaff, Hartzell V. , Pereira, Naveen L. , Luis, Sushil A , Schaff, Hartzell

Mayo Clinic

Circulation: Cardiovascular Genetics | August 3, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circgenetics.116.001661 | PMID 28768754 Get It

Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif
Yin, Xueqian , Kang, Jeong Han , Andrianifahanana, Mahefatiana, Jung, Mi-Yeon, Hernandez, Danielle M. , Leof, Edward B. , Wang, Youli

Mayo Clinic

Molecular Biology of the Cell | August 3, 2017 | Volume: 28 | Issue: 20 | Pages: 2701-2711

10.1091/mbc.e17-05-0334 | PMID 28768825 Get It

Delivery of biomolecules to the correct subcellular locales is critical for proper physiological function. To that end, we have previously determined that type I and II transforming growth factor beta (TGF-β) receptors (TβRI and TβRII, respectively) localize to the basolateral domain in polarized epithelia. While TβRII targeting was shown to be regulated by sequences between amino acids 529 and 538, the analogous region(s) within TβRI is unknown. To address that question, sequential cytoplasmic TβRI truncations and point mutations identified a targeting motif between residues 158 and 163 (VxxEED) required for basolateral TβRI expression. Further studies documented that receptor internalization, down-regulation, direct recycling, or Smad signaling were unaffected by motif mutations that caused TβRI mislocalization. However, inclusion of amino acids 148–217 containing the targeting motif was able to direct basolateral expression of the apically sorted nerve growth factor receptor (NGFR, p75; extracellular and transmembrane regions) in a dominant manner. Finally, coexpression of apically targeted type I and type II TGF-β receptors mediated Smad3 signaling from the apical membrane of polarized epithelial cells. These findings demonstrate that the absence of apical TGF-β signaling in normal epithelia is primarily a reflection of domain-specific receptor expression and not an inability to couple with the signaling machinery.
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasiv
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Penault‐Llorca, Frédérique, Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane B. , Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Moreira, André L. , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Sanders, Melinda E. , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 5 | Pages: 235-251

10.1097/pap.0000000000000162 | PMID 28777142 Get It

Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
An Uncontrolled Pilot Study of an Integrated Family-Based Partial Hospitalization Program for Youth With Mood Disorders
Leffler, Jarrod M. , Junghans-Rutelonis, Ashley N. , McTate, Emily , Geske, Jennifer R. , Hughes, Honore M., Geske, Jennifer

Mayo Clinic

Evidence-Based Practice in Child and Adolescent Mental Health | August 2, 2017 | Volume: 2 | Issue: 3-4 | Pages: 150-164

10.1080/23794925.2017.1362329 Get It

The Disputed Discovery of Facial and Trigeminal Nerve Function: Revisiting the Contributions of Herbert Mayo and Charles Bell
Carlson, Matthew L. , Bradley, James , Tubbs, R. Shane , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | August 2, 2017 | Volume: 38 | Issue: 9 | Pages: 1376-1381

10.1097/mao.0000000000001535 | PMID 28777228 Get It

Background: The first description of the voluntary motor function of the facial nerve and separate sensory-motor contributions of the trigeminal nerve is most commonly attributed to Charles Bell. However, a review of the original scientific accounts and subsequent historical publications question the validity of this credit. The objective of the present historical analysis is to clarify the contributions of Herbert Mayo toward discovering the functions of the fifth and seventh cranial nerves and to raise awareness of this historical controversy within the medical literature. Methods: Review of Charles Bell's and Herbert Mayo's original dissertations published between 1821 and 1823, and subsequent reports relevant to these primary works. Results: Bell's submissions to the Royal Society of London in 1821 and 1822 describe the seventh nerve as the “respiratory nerve of the face” responsible for involuntary coordination of facial movement with the organs of respiration. Separately, Bell states that the fifth nerve is responsible for sensibility and voluntary movement of the facial muscles. In these accounts, Bell only peripherally alludes to the motor function of the seventh nerve and often comments inaccurately on fifth and seventh cranial nerve innervation. In contrast, in 1822 and 1823, Herbert Mayo first accurately and unequivocally defined the voluntary motor function of the facial nerve and sensory-motor function of the trigeminal nerve on the basis of his detailed experiments. The ultimate transfer of acknowledgment to Bell was rooted in surreptitious reworking of Bell's original dissertations and personal attacks against Mayo rather than arguments of scientific merit. Conclusion: Several notable clinicians and anatomists have contributed to our current understanding of the anatomy and physiology of the facial and trigeminal nerves, including Charles Bell; however, Herbert Mayo should be remembered for first providing a more accurate and clear description of their separate functions.
Sudden unexpected death in epilepsy patients is often misdiagnosed as sudden cardiac death
Ryvlin, Philippe , Cascino, Gregory D. , Ryvlin, Philippe

Mayo Clinic

Neurology | August 2, 2017 | Volume: 89 | Issue: 9 | Pages: 878-879

10.1212/wnl.0000000000004301 | PMID 28768845 Get It

Transcatheter aortic valve implantation in lower-risk patients: what is the perspective?
Tarantini, Giuseppe , Fovino, Luca Nai , Gersh, Bernard J.

Mayo Clinic

European Heart Journal | August 2, 2017 | Volume: 39 | Issue: 8 | Pages: 658-666

10.1093/eurheartj/ehx489 | PMID 29020347 Get It